ERBB2 and prostate carcinoma: Specifically, lapatinib (0.8 μM), a HER2 inhibitor [37], was used for breast cancer (MCF7); gefitinib (15 μM), an EGFR inhibitor [38], for lung cancer (H358); dasatinib (70 nM), an Src inhibitor [39], for prostate cancer (LNCaP); and finally, AZD1480 (6 μM), a JAK2 inhibitor [40], for hepatocellular carcinoma.